Akadeum Life Sciences to Provide Clinical & Tech Updates, Moderate Panel Alongside Industry Leaders at Cell & Gene Meeting on the Mesa
ANN ARBOR, Mich., Oct. 2, 2025 /PRNewswire/ -- Akadeum Life Sciences, a leader in buoyancy-based cell separation technology, will present significant milestone updates of its next-generation cell isolation microbubble technology at the annual Cell & Gene Meeting on the Mesa, taking place October 6–8, 2025, at the historic Arizona Biltmore Resort. Akadeum will also moderate a high-profile Science Slam session with industry leaders on the topic of improving the time and cost to develop therapeutics.
Learn More at the Following Events:
On Monday, October 6th, at 4:00 PM in Frank Lloyd Wright Ballroom F, Akadeum's Vice President of Research and Development, Dr. Bill Lloyd, will moderate "Quality, Speed, Cost – Pick Three," a Science Slam featuring a panel of industry leaders discussing emerging technologies that deliver quality, speed, and cost efficiency in cell and gene therapy research and manufacturing. The session will drive home the need for greater access and affordability of therapeutics and how that can be realized, a topic relevant to Akadeum's microbubbles that provide up to 40% overall reduction in costs and reduce cell therapy production time by up to four days with more potent, persistent cells.
Panelists
- Jason Bock, PhD, Founder and CEO, CTMC
- Shannon Eaker, PhD, Chief Technology Officer, Xcell Biosciences
- Adam Bryan, Vice President, Personalized Medicine Business Unit Head, Lonza Cell & Gene
- Bill Lloyd, PhD, Vice President of R&D, Akadeum Life Sciences
On Tuesday, October 7th, at 5:15 PM in Frank Lloyd Wright Ballroom G, Akadeum's CEO, Dr. Brandon McNaughton, will take the stage to present how Akadeum's innovative negative selection cell separation platform overcomes core industry challenges—including time, cost, cell health, and scalability—empowering developers to achieve better therapeutics. The presentation will include updates on Akadeum's regulatory accomplishments, clinical milestones and data from collaborators demonstrating improved potency and the ability to reduce vein-to-vein time by days when using microbubbles for cell isolation. Taken together, Dr. McNaughton's presentation will demonstrate how microbubble-based cell separation is the path to better therapies.
"Akadeum's mission is to remove barriers so that more can access life-changing therapies," said McNaughton. "We're thrilled to be a part of the conversation that will help shape the future of cell and gene therapy."
Throughout the meeting, Akadeum's team will be onsite to discuss how microbubble cell separation technology can be seamlessly integrated into existing workflows, simplifying and accelerating high-quality cell isolation without requiring new equipment while also minimizing GMP suite space and labor costs. Attendees interested in collaborative opportunities are encouraged to schedule meetings with CEO Dr. Brandon McNaughton, CFO Jim Militello, VP of R&D Dr. Bill Lloyd, or VP of Sales Alex Bukrinsky through Meeting on the Mesa's partneringONE® platform or the Akadeum website: https://www.akadeum.com/contact/
About Akadeum Life Sciences
Akadeum Life Sciences is dedicated to advancing cell separation technology through its unique buoyant microbubble platform, enabling researchers and manufacturers to achieve higher yields, better purity, and improved process simplicity across a range of life science applications. Our mission is to create separation technologies to advance human health. We envision a world where innovative separations empower researchers and clinicians to unlock breakthroughs in diagnostics, therapeutics, and basic research. For more information, visit www.akadeum.com.
Media Contact:
Brandon McNaughton, PhD
Chief Executive Officer
info@akadeum.com
734-707-1233
View original content to download multimedia:https://www.prnewswire.com/news-releases/akadeum-life-sciences-to-provide-clinical--tech-updates-moderate-panel-alongside-industry-leaders-at-cell--gene-meeting-on-the-mesa-302573558.html
SOURCE Akadeum Life Sciences Inc